Mycobacterium intracellulare pulmonary disease with endobronchial caseation in a patient treated with methotrexate

Jin Sun Park; Eul Sik Jung; Woosuk Choi; Soo Yong Park; Min Young Rim; Inku Yu; Hyeonsu Park; Sang Min Lee; Jeong Woong Park; Sung Hwan Jeong; Sang Pyo Lee; Sanghui Park

doi:10.4046/trd.2013.75.1.28

Mycobacterium intracellulare pulmonary disease with endobronchial caseation in a patient treated with methotrexate

Jin Sun Park, Eul Sik Jung, Woosuk Choi, Soo Yong Park, Min Young Rim, Inku Yu, Hyeonsu Park, Sang Min Lee, Jeong Woong Park, Sung Hwan Jeong, Sang Pyo Lee, Sanghui Park

Department of Pathology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Methotrexate (MTX) has been established as a standard disease-modifying anti-rheumatic drug. If adequate disease control is achieved for a reasonable period of time, tapering the MTX dosage is recommended because the chronic use of MTX can result in opportunistic infection. We present here a case of a woman with rheumatoid arthritis taking MTX, and the woman developed actively caseating endobronchial Mycobacterium intracellulare disease with pulmonary infiltrations. After discontinuing the MTX, the patient was able to tolerate 18 months of antimycobacterial treatment without flare ups of rheumatoid arthritis, and she completely recovered from nontuberculous mycobacterial respiratory disease.

Original language	English
Pages (from-to)	28-31
Number of pages	4
Journal	Tuberculosis and Respiratory Diseases
Volume	75
Issue number	1
DOIs	https://doi.org/10.4046/trd.2013.75.1.28
State	Published - Jul 2013

Keywords

Arthiritis, rheumatoid
Bronchial diseases
Methotrexate
Nontuberculous mycobacteria
Tuberculosis, pulmonary

Access to Document

10.4046/trd.2013.75.1.28

Cite this

@article{456ad434c7ba448693079dcc779bdab9,

title = "Mycobacterium intracellulare pulmonary disease with endobronchial caseation in a patient treated with methotrexate",

abstract = "Methotrexate (MTX) has been established as a standard disease-modifying anti-rheumatic drug. If adequate disease control is achieved for a reasonable period of time, tapering the MTX dosage is recommended because the chronic use of MTX can result in opportunistic infection. We present here a case of a woman with rheumatoid arthritis taking MTX, and the woman developed actively caseating endobronchial Mycobacterium intracellulare disease with pulmonary infiltrations. After discontinuing the MTX, the patient was able to tolerate 18 months of antimycobacterial treatment without flare ups of rheumatoid arthritis, and she completely recovered from nontuberculous mycobacterial respiratory disease.",

keywords = "Arthiritis, rheumatoid, Bronchial diseases, Methotrexate, Nontuberculous mycobacteria, Tuberculosis, pulmonary",

author = "Park, {Jin Sun} and Jung, {Eul Sik} and Woosuk Choi and Park, {Soo Yong} and Rim, {Min Young} and Inku Yu and Hyeonsu Park and Lee, {Sang Min} and Park, {Jeong Woong} and Jeong, {Sung Hwan} and Lee, {Sang Pyo} and Sanghui Park",

year = "2013",

month = jul,

doi = "10.4046/trd.2013.75.1.28",

language = "English",

volume = "75",

pages = "28--31",

journal = "Tuberculosis and Respiratory Diseases",

issn = "1738-3536",

publisher = "The Korean Academy of Tuberculosis and Respiratory Diseases",

number = "1",

}

TY - JOUR

T1 - Mycobacterium intracellulare pulmonary disease with endobronchial caseation in a patient treated with methotrexate

AU - Park, Jin Sun

AU - Jung, Eul Sik

AU - Choi, Woosuk

AU - Park, Soo Yong

AU - Rim, Min Young

AU - Yu, Inku

AU - Park, Hyeonsu

AU - Lee, Sang Min

AU - Park, Jeong Woong

AU - Jeong, Sung Hwan

AU - Lee, Sang Pyo

AU - Park, Sanghui

PY - 2013/7

Y1 - 2013/7

N2 - Methotrexate (MTX) has been established as a standard disease-modifying anti-rheumatic drug. If adequate disease control is achieved for a reasonable period of time, tapering the MTX dosage is recommended because the chronic use of MTX can result in opportunistic infection. We present here a case of a woman with rheumatoid arthritis taking MTX, and the woman developed actively caseating endobronchial Mycobacterium intracellulare disease with pulmonary infiltrations. After discontinuing the MTX, the patient was able to tolerate 18 months of antimycobacterial treatment without flare ups of rheumatoid arthritis, and she completely recovered from nontuberculous mycobacterial respiratory disease.

AB - Methotrexate (MTX) has been established as a standard disease-modifying anti-rheumatic drug. If adequate disease control is achieved for a reasonable period of time, tapering the MTX dosage is recommended because the chronic use of MTX can result in opportunistic infection. We present here a case of a woman with rheumatoid arthritis taking MTX, and the woman developed actively caseating endobronchial Mycobacterium intracellulare disease with pulmonary infiltrations. After discontinuing the MTX, the patient was able to tolerate 18 months of antimycobacterial treatment without flare ups of rheumatoid arthritis, and she completely recovered from nontuberculous mycobacterial respiratory disease.

KW - Arthiritis, rheumatoid

KW - Bronchial diseases

KW - Methotrexate

KW - Nontuberculous mycobacteria

KW - Tuberculosis, pulmonary

UR - http://www.scopus.com/inward/record.url?scp=84882808087&partnerID=8YFLogxK

U2 - 10.4046/trd.2013.75.1.28

DO - 10.4046/trd.2013.75.1.28

M3 - Article

C2 - 23946756

AN - SCOPUS:84882808087

SN - 1738-3536

VL - 75

SP - 28

EP - 31

JO - Tuberculosis and Respiratory Diseases

JF - Tuberculosis and Respiratory Diseases

IS - 1

ER -

Mycobacterium intracellulare pulmonary disease with endobronchial caseation in a patient treated with methotrexate

Abstract

Keywords

Access to Document

Fingerprint

Cite this